Follow the Atrium Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €219.6m. The latest transaction was filed on 22 April 2026 (Attribution). Among the most active insiders: Younis Husam. The full history is openly available.
6
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Atrium Therapeutics, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$25.00.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.